{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:24:20Z","timestamp":1776432260037,"version":"3.51.2"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ecl.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T02:16:10Z","timestamp":1340158570000},"page":"507-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Anabolic Therapies for Osteoporosis"],"prefix":"10.1016","volume":"41","author":[{"given":"Alexander V.","family":"Uihlein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Z.","family":"Leder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2012.05.002_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"Riggs","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1084\/jem.49.1.145","article-title":"Studies of calcium and phosphorus metabolism: V. A study of the bone trabeculae as a readily available reserve supply of calcium","volume":"49","author":"Bauer","year":"1929","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(76)92216-9","article-title":"Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis","volume":"1","author":"Reeve","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2012.05.002_bib4","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","article-title":"Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial","volume":"280","author":"Reeve","year":"1980","journal-title":"Br Med J"},{"key":"10.1016\/j.ecl.2012.05.002_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/jbmr.5650010411","article-title":"Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D","volume":"1","author":"Slovik","year":"1986","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/bmj.301.6747.314","article-title":"Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride","volume":"301","author":"Reeve","year":"1990","journal-title":"BMJ"},{"key":"10.1016\/j.ecl.2012.05.002_bib7","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02556561","article-title":"Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients","volume":"44","author":"Hesch","year":"1989","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ecl.2012.05.002_bib8","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1172\/JCI116273","article-title":"An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis","volume":"91","author":"Hodsman","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2012.05.002_bib10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/endo-110-2-506","article-title":"Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration","volume":"110","author":"Tam","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2012.05.002_bib11","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2012.05.002_bib13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bone.2008.10.037","article-title":"Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts","volume":"44","author":"Jilka","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2012.05.002_bib14","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","article-title":"Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells","volume":"136","author":"Dobnig","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2012.05.002_bib15","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2012.05.002_bib16","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2011.10.044","article-title":"Update on Wnt signaling in bone cell biology and bone disease","volume":"492","author":"Monroe","year":"2012","journal-title":"Gene"},{"key":"10.1016\/j.ecl.2012.05.002_bib18","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1359\/jbmr.2002.17.9.1570","article-title":"Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone","volume":"17","author":"Bikle","year":"2002","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib19","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1210\/endo-124-3-1247","article-title":"Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone","volume":"124","author":"McCarthy","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2012.05.002_bib20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0006-291X(89)92795-2","article-title":"Activation of the bone-derived latent TGF beta complex by isolated osteoclasts","volume":"158","author":"Oreffo","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ecl.2012.05.002_bib21","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bone.2009.07.091","article-title":"Rapid and robust response of biochemical markers of bone formation to teriparatide therapy","volume":"45","author":"Glover","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2012.05.002_bib22","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib24","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib25","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib27","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1210\/jc.2002-020334","article-title":"A\u00a0randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis","volume":"87","author":"Body","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib28","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib29","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib30","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1359\/jbmr.070104","article-title":"Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium","volume":"22","author":"Lindsay","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A\u00a0novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bone.2008.09.019","article-title":"Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84","volume":"44","author":"Recker","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2012.05.002_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1359\/jbmr.061011","article-title":"Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis","volume":"22","author":"Keaveny","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib34","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1359\/jbmr.080805","article-title":"Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans","volume":"23","author":"Keaveny","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2012.05.002_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib37","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib38","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI3914","article-title":"Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial","volume":"102","author":"Lane","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2012.05.002_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib40","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2012.05.002_bib41","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib42","first-page":"3069","article-title":"Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers","volume":"85","author":"Kurland","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bone.2010.11.012","article-title":"Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women","volume":"48","author":"Yu","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2012.05.002_bib44","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1210\/jc.2007-2781","article-title":"Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling","volume":"93","author":"Black","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib45","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib46","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1210\/jc.2009-0154","article-title":"Effects of teriparatide retreatment in osteoporotic men and women","volume":"94","author":"Finkelstein","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1359\/jbmr.081250","article-title":"Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate","volume":"24","author":"Cosman","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/jc.2009-0358","article-title":"Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women","volume":"95","author":"Cosman","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib49","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00198-006-0159-1","article-title":"Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study","volume":"17","author":"Matsumoto","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2012.05.002_bib50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ecl.2012.05.002_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1359\/JBMR.051020","article-title":"Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy","volume":"21","author":"Ste-Marie","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1359\/JBMR.050714","article-title":"Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial","volume":"20","author":"Deal","year":"2005","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib54","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib55","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib57","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib58","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-010-1379-y","article-title":"Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide","volume":"22","author":"Blumsohn","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2012.05.002_bib59","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib60","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2012.05.002_bib61","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib62","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2012.05.002_bib63","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ecl.2012.05.002_bib64","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1210\/en.2002-220149","article-title":"Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH","volume":"143","author":"Sato","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2012.05.002_bib65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/01926230490462138","article-title":"Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose","volume":"32","author":"Vahle","year":"2004","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ecl.2012.05.002_bib66","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ecl.2012.05.002_bib67","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1359\/jbmr.080807","article-title":"Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]","volume":"23","author":"Vahle","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.061111","article-title":"Osteosarcoma and teriparatide?","volume":"22","author":"Harper","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib69","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00198-009-1004-0","article-title":"Of mice and men: divergent risks of teriparatide-induced osteosarcoma","volume":"21","author":"Subbiah","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2012.05.002_bib70","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1172\/JCI33612","article-title":"Building bone to reverse osteoporosis and repair fractures","volume":"118","author":"Khosla","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ecl.2012.05.002_bib71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11914-011-0089-5","article-title":"Sclerostin: therapeutic horizons based upon its actions","volume":"10","author":"Costa","year":"2012","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.ecl.2012.05.002_bib72","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib73","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib74","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib75","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/jbmr.307","article-title":"Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of non-fractured bones","volume":"26","author":"Ominsky","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib76","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.ecl.2012.05.002_bib77","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib78","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","article-title":"Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass","volume":"21","author":"Morvan","year":"2006","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2012.05.002_bib79","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bone.2006.09.004","article-title":"Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats","volume":"40","author":"Wang","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2012.05.002_bib80","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.109.164129","article-title":"The application of target information and preclinical pharmacokinetic\/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis","volume":"333","author":"Betts","year":"2010","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.ecl.2012.05.002_bib81","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1210\/jc.2002-021122","article-title":"Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis","volume":"88","author":"Horwitz","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852912000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852912000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:36:13Z","timestamp":1760175373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852912000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0889852912000527"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2012.05.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anabolic Therapies for Osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2012.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}